IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $2.95B
• Dividend Yield: N/A
• Average Volume (3M): 907.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.50
• Revenue Growth: 5376.27%
• EPS Growth: 20.97%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.47
• Shares Outstanding: 87,666,405
• 10 Day Avg. Volume: 955,390
• 30 Day Avg. Volume: 907,098
• PEG Ratio: -0.11
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 299.87
• P/FCF Ratio: -8.35
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 7.82
• Enterprise Value/Gross Profit: 7.97
• Enterprise Value/Ebitda: -10.73
• 1Y Price Target: $49.08
• Price Target Upside: 44.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -1.25
• Revenue Forecast (FY): $216.88M

• Rating: 50 Neutral
• Price Target: $34.00 ▼(-0.06% Downside)

IDEAYA Biosciences' overall stock score reflects significant financial challenges and valuation concerns, primarily due to ongoing losses and a negative P/E ratio. The technical analysis shows some positive trends, but momentum is limited. The termination of the GSK collaboration adds uncertainty, although promising clinical data provides some optimism.

Positive Factors

Pipeline Progress

The completion of full enrollment in a key trial indicates strong progress in IDEAYA's pipeline, potentially leading to accelerated approval and commercialization opportunities, enhancing long-term growth prospects.

New Drug Development

The IND submission for a new drug candidate reflects IDEAYA's ongoing innovation and potential to expand its product portfolio, which could drive future revenue and strengthen its market position in oncology.

Strong Equity Position

A strong equity position with low leverage provides IDEAYA with financial stability and flexibility to invest in R&D and strategic initiatives, supporting long-term operational resilience and growth.

Negative Factors

Collaboration Termination

The termination of a major collaboration with GSK introduces uncertainty and potential strategic realignment, which could delay development timelines and impact IDEAYA's ability to leverage external expertise and resources.

Revenue Decline

A substantial decline in revenue highlights challenges in commercial execution and market penetration, potentially affecting IDEAYA's ability to sustain operations and invest in future growth without external funding.

Cash Flow Constraints

Negative cash flow from operations indicates cash burn, which could limit IDEAYA's ability to fund ongoing R&D and clinical trials, necessitating additional financing to maintain its growth trajectory.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences (IDYA) is a biotechnology company focused on the discovery and development of targeted therapeutics for genetically defined cancers. The company specializes in precision medicine, leveraging its proprietary biology and drug discovery platforms to design and develop innovative treatments that aim to improve patient outcomes in oncology. IDEAYA's core products include a pipeline of investigational drugs targeting specific genetic mutations and pathways in cancer cells, with a commitment to addressing unmet medical needs in cancer treatment.

How the Company Makes Money

IDEAYA Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company engages in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, research funding, and milestone payments as products progress through various stages of development. Additionally, royalties from product sales may contribute to revenue once therapies are commercialized. The company also focuses on obtaining grants and funding from government and private entities to support its research initiatives, enhancing its financial stability and growth potential.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.83M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	210.79M	3.17M	19.38M	48.83M	26.22M	18.16M
EBITDA	-156.70M	-270.64M	-108.95M	-56.55M	-48.04M	-33.11M
Net Income	-160.74M	-274.48M	-112.96M	-58.66M	-49.76M	-34.49M
Balance Sheet
Total Assets	1.19B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	786.89M	676.32M	525.11M	364.83M	246.77M	283.58M
Total Debt	27.25M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	93.10M	64.94M	28.23M	38.51M	79.83M	100.00M
Stockholders Equity	1.09B	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-105.39M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-102.26M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-29.61M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	30.40M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 34.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 34.02 is below the 20-day moving average (MA) of 34.30, above the 50-day MA of 31.45, and above the 200-day MA of 23.85, indicating a neutral trend. The MACD of 0.80 indicates Positive momentum. The RSI at 53.86 is Neutral, neither overbought nor oversold. The STOCH value of 15.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.61B	―	-28.17%	―	129.21%	80.35%
BEAM	58 Neutral	$2.78B	―	-47.19%	―	-84.07%	-157.71%
TVTX	56 Neutral	$3.13B	―	-410.78%	―	114.22%	77.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDYA	50 Neutral	$2.95B	―	-14.15%	―	5376.27%	20.97%
AGIO	48 Neutral	$1.60B	―	-27.57%	―	36.26%	-158.98%
CELC	44 Neutral	$4.66B	―	-122.04%	―	―	-40.75%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Faces Collaboration Termination by GSK

On December 9, 2025, GlaxoSmithKline notified IDEAYA Biosciences of its decision to terminate their collaboration and license agreement, effective March 9, 2026. During the transition period, GSK will transfer two clinical programs back to IDEAYA, which will assess its strategic options for these programs in 2026, without affecting its cash runway expectations into 2030.

GlaxoSmithKline Ends Collaboration with IDEAYA Biosciences

On December 4, 2025, GlaxoSmithKline announced its decision to terminate its collaboration with IDEAYA Biosciences, effective ninety days from the notice. During this transition period, GSK will transfer the Werner Helicase and Pol Theta clinical programs back to IDEAYA, which plans to evaluate strategic options for these programs in 2026, maintaining its cash runway expectations into 2030.

IDEAYA Biosciences Presents Promising Phase 2 Data

On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.